Inosine-5'-monophosphate dehydrogenase (IMPDH) type II is a validated target for treating immunological diseases and inducing immunosuppression. It's the target of CellCept® (mycophenolic acid prodrug by Roche) and is recognized as a promising target for treating psoriasis, rheumatoid arthritis (RA), and systemic lupus erythematosus (SLE). Our IMPDH assay kits enable precise measurement of enzyme activity for drug discovery and research applications.

Purine nucleoside phosphorylase (PNP) deficiency is associated with T-lymphocytopenia while sparing B-lymphocyte function. This unique characteristic makes PNP an attractive target for developing selective immunosuppressive agents. Our PNP assay kits facilitate the discovery of novel inhibitors with potential applications in treating T-cell leukemias and T-cell-mediated autoimmune diseases, including lupus erythematosus and rheumatoid arthritis.

With antibiotic resistance emerging as a critical global health challenge, there's an urgent need for novel antibiotics targeting new pathways. Bacterial IMPDH, essential for de novo purine nucleotide synthesis, represents a promising target for next-generation antibiotics. Our bacterial IMPDH assay kits support the discovery of novel antimicrobial agents by enabling high-throughput screening of compounds that inhibit this crucial bacterial enzyme, potentially leading to new treatments for resistant infections.